![Neil Gallagher](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Neil Gallagher
Director/Board Member at
FOGHORN THERAPEUTICS INC.
Net worth: - $ as of 2026-09-29
Profile
Neil Gallagher is currently an Independent Director at Foghorn Therapeutics, Inc. since 2025.
Formerly, Dr. Gallagher was Director-Clinical Development at Astex Therapeutics Ltd. Dr. Gallagher was an Independent Director at Zymeworks, Inc. from 2024 to 2025.
Dr. Gallagher was President, Head-Research & Development at Syndax Pharmaceuticals, Inc. from 2023 to 2025.
Dr. Gallagher was Chief Medical Officer & Head-Development at AbbVie, Inc. from 2020 to 2023.
Dr. Gallagher was Head-Development, Oncology & Inflammation at Amgen, Inc. from 2016 to 2017.
Dr. Gallagher earned doctorates from the University of Birmingham and Trinity College Dublin.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-19 | 0 ( -.--% ) | - $ | 2026-09-29 |
Neil Gallagher active positions
| Companies | Position | Start |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Director/Board Member | 2025-04-30 |
Former positions of Neil Gallagher
| Companies | Position | End |
|---|---|---|
| ZYMEWORKS INC. | Director/Board Member | 2025-11-05 |
| SYNDAX PHARMACEUTICALS, INC. | President | 2025-05-11 |
| ABBVIE INC. | Chief Tech/Sci/R&D Officer | 2023-03-31 |
| AMGEN INC. | Corporate Officer/Principal | 2017-09-30 |
Astex Therapeutics Ltd.
 Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops fragment based drug | Corporate Officer/Principal | - |
Education of Neil Gallagher
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
76
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Syndax Pharmaceuticals, Inc.
 Syndax Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
AbbVie, Inc.
 AbbVie, Inc. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufacturing, commercialization & sale of immunology medicines and therapies | Health Technology |
Astex Therapeutics Ltd.
Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops fragment based drug | Health Technology |
Trinity College Dublin
 Trinity College Dublin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Birmingham
 University of Birmingham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Foghorn Therapeutics, Inc.
 Foghorn Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops novel drugs to treat cancer and other serious medical disorders | Health Technology |
Zymeworks, Inc.
 Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
- Stock Market
- Insiders
- Neil Gallagher
